Biomedical subjects
Publications and source records attributed to A Macías.
Atrial fibrillation, atrial flutter, paroxistical supraventricular tachycardias and atrial tachycardias are the main supraventricular arrhythmias. Atrial fibrillation is the most common. In this review we comment their physiopathology, clinical manifestations, and treatments, paying special attention to the possible esmolol applications.
The era of catheter ablation for the treatment of arrhythmias began in 1981 when Dr Scheinman performed the first atrioventricular junction ablation using direct current shocks in a patient with drug refractory atrial fibrillation and an uncontrolled ventricular rate. With the progress of radiofrequency catheter ablation, the range of arrhythmias amenable to catheter ablation and the number of patients that could be treated safely by this procedure expanded enormously. Lastly, although still in an evolutionary phase, catheter ablation to eliminate atrial fibrillation has been demostrated in the past years to be feasible and clinically useful. On the other hand, innovations in technology and pharmacology, and better preventive and diagnostic tools, have provided our patients with an important improvement in their prognosis. The new developments in molecular genetics and biology are likely to change the way we approach a cardiac patient in the future. The diseases are now being deciphered at the most basic level, and the information obtained opens new possibilities not only for better therapeutic and diagnostic measures but also for prevention of the disease.
Analysis of the receptors for estradiol and epidermal growth factor was performed in tumors from 225 breast cancer patients. The tumor cell content of both receptors was independent of clinical stage and lymph node status. There was an inverse correlation between the epidermal growth factor receptor and the estradiol receptor. Either the presence of the epidermal growth factor receptor or the lack of the estradiol receptor was related to a high relapse rate. A combination of these two receptors leads to an increased prognostic predictive capacity. Patients whose tumors contain both the estradiol receptor and epidermal growth factor receptor had a relapse rate similar to those whose tumors were estradiol receptor poor, and are thus high risk patients. Patients whose tumors contain the estradiol receptor and lack the epidermal growth factor receptor belong to a good prognosis group.
Explore the source record for details and available documents.
Explore the source record for details and available documents.